A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

被引：4

作者：

Bazinet, Alexandre ^{[1
]}

Garcia-Manero, Guillermo ^{[2
]}

Short, Nicholas J. ^{[1
]}

Valero, Yesid Alvarado ^{[1
]}

Abuasab, Tareq ^{[1
]}

Islam, Md Rabiul ^{[2
]}

Montalbano, Kathryn ^{[1
]}

Issa, Ghayas C. ^{[1
]}

Maiti, Abhishek ^{[1
]}

Yilmaz, Musa ^{[1
]}

Jain, Nitin ^{[1
]}

Masarova, Lucia ^{[1
]}

Kornblau, Steven M. ^{[1
]}

Jabbour, Elias ^{[2
]}

Montalban-Bravo, Guillermo ^{[2
]}

Pierce, Sherry ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Daver, Naval ^{[1
]}

Konopleva, Marina Y. ^{[3
,4
]}

Kantarjian, Hagop M. ^{[5
]}

Ravandi, Farhad ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Montefiore Med Ctr, Dept Oncol, 111 E 210Th St, Bronx, NY 10467 USA

[4] Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-172658

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy
Abuasab, Tareq
Alvarado, Yesid
Issa, Ghayas
Islam, Rabiul
James, Nicholas
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven
Jabbour, Elias
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Pierce, Sherry
DiNardo, Courtney
Kadia, Tapan
Daver, Naval
Konopleva, Marina
Garcia-Manero, Guillermo
Ravandi, Farhad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S237 - S237
[2] Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
Abuasab, Tareq
Garcia-Manero, Guillermo
Short, Nicholas
Alvarado, Yesid
Issa, Ghayas C.
Islam, Rubiul
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven M.
Jabbour, Elias
Pemmaraju, Naveen
Montalban-Bravo, Guillermo
Pierce, Sherry A.
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Konopleva, Marina
Kantarjian, Hagop
Ravandi, Farhad
BLOOD, 2022, 140 : 3324 - 3326
[3] Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Bazinet, Alexandre
Garcia-Manero, Guillermo
Short, Nicholas
Alvarado, Yesid
Bataller, Alex
Abuasab, Tareq
Islam, Rabiul
Montalbano, Kathryn
Issa, Ghayas
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven
Jabbour, Elias
Montalban-Bravo, Guillermo
Rausch, Caitlin R.
Pierce, Sherry
Dinardo, Courtney
Kadia, Tapan
Daver, Naval
Konopleva, Marina
Huang, Xuelin
Kantarjian, Hagop
Ravandi, Farhad
LANCET HAEMATOLOGY, 2024, 11 (04): : e276 - e286
[4] Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
Ravandi, Farhad
Abuasab, Tareq
Valero, Yesid Alvarado
Issa, Ghayas C.
Islam, Rabiul
Short, Nicholas James
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven Mitchell
Jabbour, Elias
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Pierce, Sherry
Dinardo, Courtney Denton
Kadia, Tapan M.
Daver, Naval Guastad
Konopleva, Marina
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Maiti, Abhishek
DiNardo, Courtney D.
Ohanian, Maro
Daver, Naval
Borthakur, Gautam
Chien, Kelly S.
Issa, Ghayas C.
Takahashi, Koichi
Masarova, Lucia
Valero, Yesid Alvarado
Jabbour, Elias
Wierda, William G.
Short, Nicholas J.
MacFarland, Melissa
Pike, Allison
Kadia, Tapan M.
Ravandi, Farhad
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Konopleva, Marina Y.
BLOOD, 2023, 142
[6] A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy
Nannis, Gabriel N.
Griffiths, Elizabeth A.
Savona, Michael R.
Odenike, Olatoyosi
Roboz, Gail J.
O'Connell, Casey L.
Dillingham, Jacqueline
Wason, Prieya
Zhu, Lixia
Chan, Danna
Keer, Harold N.
Oganesian, Aram
Dao, Kim-Hien
DiNardo, Courtney D.
BLOOD, 2021, 138
[7] Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia
Candoni, Anna
LANCET HAEMATOLOGY, 2024, 11 (04): : e245 - e246
[8] Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Issa, Ghayas C.
Cuglievan, Branko
DiNardo, Courtney D.
Short, Nicholas J.
McCall, David
Gibson, Amber
Nunez, Cesar
Garcia, Miriam B.
Roth, Michael
Bidikian, Aram
Pike, Allison
Tan, Sheila
Kammerer, Brianna
Yilmaz, Musa
Kadia, Tapan M.
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval
Jabbour, Elias
Borthakur, Gautam
Ravandi, Farhad
Garcia-Manero, Guillermo
Andreeff, Michael
Kantarjian, Hagop M.
BLOOD, 2023, 142
[9] Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
Savona, Michael R.
McCloskey, James K.
Griffiths, Elizabeth A.
Yee, Karen
Zeidan, Amer M.
Al-Kali, Aref
Deeg, H. Joachim
Patel, Prapti
Sabloff, Mitchell
Keating, Mary-Margaret
Dao, Kim-Hien
Zhu, Nancy
Gabrail, Nashat
Fazal, Salman
Maly, Joseph
Odenike, Olatoyosi
Kantarjian, Hagop
DeZern, Amy E.
O'Connell, Casey L.
Roboz, Gail J.
Busque, Lambert
Wells, Richard A.
Amin, Harshad
Randhawa, Jasleen K.
Leber, Brian
Hao, Yong
Keer, Harold N.
Azab, Mohammad
Garcia-Manero, Guillermo
Amin, Harshad
Randhawa, Jasleen K.
Leber, Brian
Hao, Yong
Keer, Harold N.
Azab, Mohammad
Garcia-Manero, Guillermo
BLOOD, 2021, 138 : 3682 - +
[10] Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
Bazinet, Alexandre
Daver, Naval
Ravandi, Farhad
Short, Nicholas J.
Yilmaz, Musa
Ohanian, Maro
Ishizawa, Jo
Maiti, Abhishek
Dinardo, Courtney D.
Masarova, Lucia
Wierda, William G.
Chien, Kelly S.
Jabbour, Elias
Hammond, Danielle
Haddad, Fadi G.
Sasaki, Koji
Bataller, Alex
Bull-Linderman, Debra
Borthakur, Gautam
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Kadia, Tapan M.
BLOOD, 2024, 144 : 4277 - 4279

← 1 2 3 4 5 →